Company profile
PMGC Holdings Inc.
NASDAQ: ELAB · Healthcare · Biotechnology
#925 of 1,422 Healthcare companies by revenuebottom-quartile growth
EA Score
29DFH 44DQ 7GM —SS 31
v0.1 · 55/100 weight · provisional
↑ balance-sheet leverage, Altman-Z · ↓ disclosure history, listing tenure
Methodology →Revenue TTM
$1.3M
Rev growth YoY (TTM)
-172.8%
Net income (FY)
-$7.7M
Employees
33
as of 2026-08-25
Market cap
$3.0M
as of 2026-08-25
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$590.1k$590.1k2025
Net income-$7.7M-$7.7M2025
Total assets$12.9M$12.9M2025
Liabilities$5.0M$5.0M2025
Equity$7.8M$7.8M2025
Revenue trend
FY2023 – FY2025 · USD
FY23
FY23
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is PMGC Holdings Inc.’s revenue?
PMGC Holdings Inc. booked $590.1k in FY2025 revenue, contracting 66% year over year — slower than 85% of Healthcare companies we track, at a -1313.0% net margin.
Peers · Healthcare
Vaccinex, Inc.——CBD of Denver, Inc.35DCardiff Oncology, Inc.53DGrapefruit USA, Inc.——Theralase Technologies Inc.37DErnexa Therapeutics Inc.43DNeighbors
Orange →Key facts
CEOGraydon Bensler
SectorHealthcare
IndustryBiotechnology
HeadquartersNewport Beach, CA
ExchangeNASDAQ: ELAB
Employees33
IPO date2023-11-21
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.